NFE2L2 and type 2 diabetes mellitus: In a phase II clinical trial for type 2 diabetes mellitus (T2DM) patients with chronic kidney disease, a C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid-methyl ester (CDDO-Me), another electrophilic NRF2 activator, significantly improved glomerular filtration rates for up to one year beyond treatment [16].